

1653
#4Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

RECEIVED TRANSMITTAL FORM
DEC 10 2001
TECH CENTER 1500/2800
(to be used for all correspondence after initial filing)

Application Number	09/927,832
Filing Date	August 10, 2001
First Named Inventor	Gyorkos
Group Art Unit	1653
Examiner Name	unknown
Attorney Docket Number	361239-020A

Total Number of Pages in This Submission >500

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
- ☐ Fee Attached
- ☐ Amendment / Reply
- ☐ After Final
- ☒ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/Incomplete Application
- ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) (please identify below):
PTO 1449 references postcard

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENTFirm
or
Individual name

Eric A. Meade, Registration Number 42,876

Signature

E. A. Meade

Date

November 20, 2001

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 11/20/2001

Typed or printed name

Eric A. Meade

Signature

E. A. Meade

Date

November 20, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



SERIAL NO.: 09/927,832
DOCKET NO.: 361239-020A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Gyorkos, et al.	
Serial No.:	09/927,832	Art Unit: 1653
Filing Date:	August 10, 2001	Examiner: Unknown
For:	Serine Protease Inhibitors	
Docket No.	361239-020A	

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.56

Applicants herein make available to the Patent and Trademark Office copies of the documents:

- ☒ listed on enclosed Form PTO/SB/08A/B (Formerly PTO-1449), in accordance with 37 CFR 1.98(a)(2); and
- ☐ listed on enclosed copies of Forms PTO-1449, PTO-892 or PTO/SB/08A/B, which forms recited the application information for applications to which this application claims priority under 35 U.S.C. §120, but have been edited to indicate the current application data. Pursuant to 37 CFR 1.98(d), NO COPIES OF THESE DOCUMENTS ARE ENCLOSED. The prior application that provides the source of these documents is:

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of this application. It is believed that the Examiner will concur with Applicant's belief that the foregoing references do not adversely affect the patentability of the subject matter presently claimed, taken alone or in combination.

It is requested that the listed references be included in the "References Cited" portion of any patent issuing from this application.

Under 37 CFR 1.97(i), Applicants understand that non-complying Information Disclosure Statements will be placed in the file but not considered by the Office, however, under Reply to Comment 8 of the Federal Register, page 2024, Applicants will be informed when information is not considered.



SERIAL NO.: 09/927,832
DOCKET NO.: 361239-020A

(1) **This Information Disclosure Statement is being filed:**

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 CFR 1.491 of the international application.
- ☒ **before** the mailing date of a first Office Action on the merits.
- ☐ **after** the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by:
- ☐ the Statement under 37 CFR 1.97(e) (see "Statement" below);
- or**
- ☐ the Fee of \$180.00 set forth in 37 CFR 1.17(p); or
- ☐ No fee is owed by the applicants.
- ☐ **after** the mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by the Statement under 37 CFR 1.97(e), a Petition requesting consideration of the Information Disclosure Statement and the Petition Fee of \$130.00 set forth in 37 CFR 1.17(i)(1) (see "Statement," "Petition," and "Fees" below).

(2) **Statement**

- ☐ The **undersigned attorney** hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

(If this box is checked, do not check any further Statement boxes.)

or

- ☐ The **person signing immediately below** hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.



SERIAL NO.: 09/927,832
DOCKET NO.: 361239-020A

The person making the statement is:

☐ the inventor(s) who sign(s) below:

Signature of the Inventor(s)

Typed or Printed Name of the Inventor(s)

or

☐ a person who is substantively involved in the preparation or prosecution of the application, and who is associated with the inventor(s), or with the assignee, or with anyone to whom there is an obligation to assign the application (37 CFR 1.565(c)) and who signs below:

Signature of the Person(s)

Typed or Printed Name of the Person

Address of Person Signing

or

☒ the undersigned agent who signs on the basis of the information:

- ☒ supplied by the inventor(s).
- ☒ supplied by an individual designated in 37 CFR 1.56(c).
- ☒ in the attorney's file.

E. C. Menden

Signature of the Agent

(3) Petition

☐ Applicants hereby petitions the Assistant Commissioner to consider the references listed in this Information Disclosure Statement and on the enclosed Form PTO/SB/08A and 08B (Formerly PTO-1449), in the examination of the above-identified patent application. *(This box checked only if a Final Office Action has issued)*



SERIAL NO.: 09/927,832
DOCKET NO.: 361239-020A

(4)

- ☒ **No Fee** is owed by the applicants.
- ☐ **The IDS Fee** of \$180.00 under 37 CFR 1.17(p) is enclosed herewith.
- ☐ **The Petition Fee** of \$130.00 under 37 CFR 1.17(i)(1) is enclosed herewith.

(5) **Method of Payment of Fees**

- ☐ Attached is a check in the amount of \$240.00.
- ☐ Charge Account No. 04-0480 in the amount of \$ _____. (A duplicate of this request is attached).

(6) **Authorization to Charge Additional Fees**

- ☒ If any additional fees are owed in connection with this communication, please charge Deposit Account No. 04-0480.

(7) **Instructions as to Overpayment**

- ☒ Please credit Account No. 04-0480 for any overpayment.
- ☐ Please refund Dechert Price & Rhoads in the amount of \$ _____.




SERIAL NO.: 09/927,832
DOCKET NO.: 361239-020A

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: November 20, 2001


Eric A. Meade
Registration No. 42,876
for
Allen Bloom
Registration No. 29,135
Attorney for Applicants

DECHERT
Princeton Pike Corporate Center
PO Box 5218
Princeton, New Jersey 08543-5218
(609)-620-3214

122706.2.07



Form PTO - 1449 U.S. Department of Commerce (Modified) Patent and Trademark Office	Attorney Docket No. 361239-020A Serial No.: 09/927,832 Applicant: Gyorkos, et al. Filing Date: August 10, 2001 Group No. 1653
Information Disclosure Statement by Applicant (use several Sheets if necessary)	

U.S. PATENT DOCUMENTS

Exmr Initial	Patent Number	Issue Date	Patentee	Class	Sub- Class	Note
AA	4,338,453	7/6/82	Gall			
BB	5,055,450	10/8/91	Edwards, et al.			
CC	5,164,371	11/17/92	Edwards, et al.			
DD	5,550,139	8/27/96	Groutas			
EE	5,618,792	4/8/97	Gyorkos, et al.			
FF	5,801,148	9/1/98	Gyorkos, et al.			
GG	5,807,829	9/15/98	Gyorkos, et al.			
HH	5,861,380	1/19/99	Gyorkos, et al.			
II	5,869,455	2/9/99	Gyorkos, et al.			
JJ	5,874,585	2/23/99	Gyorkos, et al.			
KK	6,001,814	12/14/99	Gyorkos, et al.			
LL	6,004,933	12/21/99	Spruce, et al.			
MM	6,015,791	1/18/00	Gyorkos, et al.			
NN	6,037,325	3/14/00	Gyorkos, et al.			
OO	6,150,334	11/21/00	Gyorkos, et al.			
PP	6,159,938	12/12/00	Gyorkos, et al.			
QQ	08/985,298 09/927,832 (instant) 09/928,117	Pending Application	Gyorkos, et al.			Specification cumulative in three filed applications

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Exmr Initial	Document Number	Publn Date *	Country or Patent Office	Class	Sub- Class	Translation? Yes No
RR	1 397 073	5/19/71	Europe			
SS	2 224 338	5/18/72	Germany			
TT	0 291 234 A2	5/5/88	Europe			
UU	0 480 044 A1	3/26/91	Europe			
VV	2 694 295	7/28/92	France			
WW	0 528 633 A1	8/12/92	Europe			
XX	0 529 568 A1	8/24/92	Europe			
YY	WO 93/21212	10/28/93	PCT			
ZZ	WO 95/33762	12/14/95	PCT			
AB	WO 96/16080	5/30/96	PCT			



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Place of Publication**)		
AC		Edwards, et al., Peptidyl a-Ketoheterocyclic Inhibitors of Human Neutrophil Elastase., J. Med. Chem., 1995, 38, Pg. 3972-3982.
AD		Edwards, et al., Nonpeptidic Inhibitors of Human Neutrophil Elastase., J. Med. Chem., 1996, 39, Pg. 1112-1124.
AE		Edwards, et al., Peptidyl a-Ketoheterocyclic Inhibitors of Human Neutrophil Elastase., J. Med. Chem., 1995, 38, Pg. 76-85
AF		Veale, et al., Non-peptidic Inhibitors of Human Leukocyte Elastase., J. Med. Chem., 1995, 38, Pg. 86-97.
AG		Veale, et al., Nonpeptidic Inhibitors of Human Leukocyte Elastase., J. Med. Chem., 1995, 38, Pg. 98-108.
AH		Goddard, Antiinflammatory 1-Phenylpyrazole-4-Heteroarylalkanoic Acids., J. Med. Chem., 1991, 28, Pg. 1607-1612.
AI		LaMattina, et al., Utility of p-Nitrophenyl 3-Bromo-2,2-diethoxypropionate (NPBDP) in Heterocyclic Synthesis., J. Org. Chem., 1984, 49, Pg. 4800-4805.
AJ		Unangst, et al., Novel 1,2,4-Oxadiazoles and 1,2,4-Thiadiazoles as Dual 5-Lipoxygenase and Cyclooxygenase Inhibitors., J. Med. Chem., 1992, 35, Pg. 3691-3698.
AK		Kitatani, et al., A Novel Oxazole Synthesis Utilizing Tungsten (VI) Catalyzed Decomposition of a-Diazo Carbonyl Compounds in Nitriles., Tetrahedron Letters, 1974, 16, Pg. 1531-1532.
AL		Wiley, The Chemistry of the Oxazoles., 1945, 37, Pg. 401-443.
AM		Davidson, et al., The Action of Ammonia on Benzoil., 1937, 2, Pg. 328-334.
AN		Wiegand, et al., Polyphosphoric Acid Cyclization of Acetamidoketones to 2,5-Dimethyl-1,3-oxazoles., Synthesis, 1970, 12, Pg. 648-649.
AO		Wasserman, et al., The Oxazole-Triamide Rearrangement., Tetrahedron Letters, 1982, 23(37), Pg. 3831-3834.
AP		Cornforth, A New Synthesis of Oxazoles and Iminazoles including its Application to the Preparation of Oxazole., J. Chem. Soc., 1947, 96, Pg. 96-102.
AQ		Cornforth, Synthesis of Oxazoles from Ethyl Acetoacetate. J. Chem. Soc., 1953, 93, Pg. 93-98.
AR		Bernstein, Nonpeptidic Inhibitors of Human Leukocyte Elastase., J. Med. Chem., 1994, 37, Pg. 3313-3326.
AS		Brown, Design of Orally Active, Non-Peptide Inhibitors of Human Leukocyte Elastase., Amer. Chem. Soc., 1994, 37(9), Pg. 1259-1261.
AT		Warner, et al., J. Med. Chem., Non-Peptidic Inhibitors of Human Leukocyte Elastase., 1994, 37, Pg. 3090-3099.
AU		Budavari, The Merck Index., Cefazedone, 1989, Pg. 294.
AV		Damewood, Nonpeptidic Inhibitors of Human Leukocyte Elastase., 1994, 37, Pg. 3303-3312.
Examiner		Date Considered

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO - 2)

* Use publication date indicated on the patent or published application. 37 CFR 1.98(b).

** The place or publication refers to the name of the journal, magazine or other publication in which the article was published. Notice of January 9, 1992, 1135 O.G. 13 to 25 at 20.